A recent study from the Pharmacology Institute, University of Heidelberg, Heidelberg, Germany; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA shows that the Serine protease inhibitor-A3N attenuates neuropathic pain by inhibiting T cell–derived leukocyte elastase. This study was published in the 27 April 2015 issue of the Journal “Nature Medicine” (the no.1 journal in General medicine with an impact factor of >28) by Prof.Dr. Kuner, Vicuna and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Interleukin-based neuropathic pain relieving therapy: Interleukin-1β (IL-1β) inhibits neuropathic pain via down regulation of T cell–derived leukocyte elastase
The mechanistic basis of Neuropathic pain is far from clear. This study suggests that, IL-1β, by increasing the expression of its target gene, it may decrease the expression of T cell–derived leukocyte elastase. Thereby, it may relieve neuropathic pain. Thus, pharmacological formulations encompassing “IL-1β activators” may be used to inhibit Neuropathic pain.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Citation: Boominathan, Interleukin-based neuropathic pain relieving therapy: Interleukin-1β (IL-1β) inhibits neuropathic pain via down regulation of T cell–derived leukocyte elastase, 6/May/2015, 12.11 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
Undisclosed information: How IL-1β decreases the expression of T cell–derived leukocyte elastase
* Research cooperation